319 results
Page 4 of 16
6-K
x6q1z77da
13 Jul 16
Current report (foreign)
12:00am
6-K
EX-99.1
hmos1onozg xlbuq
18 Apr 16
First-HD Study shows improvements in Total Motor Score and Swallowing Function in Huntington disease patients treated with SD-809
12:00am
6-K
EX-99.1
2s7kyjq
12 Apr 16
Teva to Present Data Highlighting Company’s Pipeline in Neurological Disorders at 68th AAN Annual Meeting
12:00am
6-K
EX-99.1
st986eu
30 Sep 15
IMPORTANT NEW DATA FROM TEVA’S TEV-48125 PHASE 2b MIGRAINE PROGRAM PUBLISHED INLANCET NEUROLOGYIN BACK-TO-BACK ARTICLES
12:00am
6-K
EX-99.1
1nfxapj tdt9
28 Sep 15
Teva Announces Approval of COPAXONE® in Japan for the Prevention of Relapse of Multiple Sclerosis
12:00am
6-K
EX-99.1
07sh ski2p
27 Jul 15
Teva to Acquire Allergan Generics for $40.5 Billion
12:00am
6-K
EX-99.1
bc1qdw46d
23 Mar 15
Live Filing
12:00am
6-K
EX-99.1
vx1rbsc
25 Feb 15
Live Filing
12:00am
6-K
EX-99.1
1jrs th1zi
24 Feb 15
TEVA ANNOUNCES POSITIVE RESULTS FOR TEV-48125 IN PHASE IIb CHRONIC MIGRAINE STUDY MEETING PRIMARY AND SECONDARY ENDPOINTS
12:00am
6-K
EX-99.1
9zb9w qz95ohjimo8
23 Feb 15
Live Filing
12:00am
6-K
EX-99.1
d77ncb7hv0lh
20 Feb 15
Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
12:00am
6-K
EX-99.1
e1rujt6n5 tp6cjvqsq
20 Jan 15
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE®20 mg/mL Case and Remand for Further Review
12:00am
6-K
EX-99.1
ms8btxud51uwx
23 Dec 14
Live Filing
12:00am
6-K
EX-99.1
mcinixubi l1ditss621
19 Dec 14
First Waterless Nasal Allergy Spray Approved for Children as Young as Four Years of Age
12:00am
6-K
EX-99.1
yh9i b3wgc8umm
4 Dec 14
Live Filing
12:00am
6-K
EX-99.1
wqk1c0wv3fw9ur7u8dx
18 Nov 14
Live Filing
12:00am
6-K
5n578
7 Nov 14
Late Stage Data to be Presented at ACAAI 2014
12:00am